The Pharmaceutical Market: Ireland

Publisher Name :
Date: 25-Apr-2013
No. of pages:

THE PHARMACEUTICAL MARKET: IRELAND – REVIEW

Ireland has experienced rapid economic growth over the past 20 years, and has invested in large scale renovation and redevelopment of its healthcare infrastructure. That said, the country is in the midst of a severe economic downturn, with GDP expected to contract in 2012. Due to the recession and Ireland’s huge budget deficit, the country has received an 85 billion euro (US$113 billion) bailout from the EU and IMF. As a result, the government faces an extremely tight financial operating environment in the next few years. It has generally sought to protect healthcare, especially frontline services, from the kinds of cuts experienced elsewhere, but health is not unaffected. A progression of measures has been introduced as the economic position has worsened, most recently the Budget 2011 and related National Recovery Plan.

In March 2011, the government announced plans to introduce Universal Health Insurance (UHI) by 2016. Underpinning the UHI system will be the principle of access according to need and payment according to ability to pay. Insurance with a public or private insurer will be compulsory, with insurance payments related to ability to pay. The government is also planning to remove fees for GP care, which will be implemented in phases, firstly for claimants of free drugs under the Long-Term Illness scheme and the High-Tech Drugs scheme, before being extended to all. Under UHI, public hospitals will no longer be managed by the HSE. They will be independent, not-for-profit trusts with managers accountable to their boards. Hospitals will be paid according to the care they deliver and will be incentivised to deliver more care in a ‘money follows the patient’ system. The government has also reiterated plans to introduce reference pricing and generic substitution, as cost saving measures.

Most global companies have some manufacturing presence in the pharmaceutical market in Ireland. Drugs are either produced in finished form for export, or exported on to other facilities for finishing. A number of branded drugs go off patent in 2012, including Pfizer’s Lipitor and Eli Lilly’s Zyprexa, which could have a negative impact on the industry. However, several multinational companies have been moving into the biologic sector in preparation for the loss of profit from these blockbuster drugs. While the multinational presence is very strong, Ireland has very few domestic producers. In September 2011, Alkermes completed its merger with Elan Drug Technologies (EDT) to form a new company, Alkermes Plc., which is headquartered in Dublin. In September 2011, Pfizer announced it was to invest US$200.0 million at its Grange Castle site, to add two processing suites and to expand current production and product testing capabilities. In September 2011, MSD opened its new R&D centre at its Ballydine site, creating 70 new jobs. Previously, in June 2011, MSD opened two new facilities at the site in Brinny.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

The Pharmaceutical Market: Ireland

Table Of Contents
N/A

  • Global Stem Cell Therapy Industry Witnesses Steady Growth
    Stem cell research which is one of the most contemporary areas of biology has developed rapidly in the last couple of years. Increased funding in stem cell research by both government and private organizations is one of the main drivers in the stem cell therapy industry. Stem cells are used in various medical therapies such [...]
  • Global Lubricant Market Driven by Increased Demand in Automotive Industry
    With growth in the automobile industry, the demand for lubricants has also increased. The robust growth in manufacturing with increase in industrial production, particularly in countries such as China and India are also fueling the demand for lubricants. In 2013, the global market for lubricants had reached a value of 123.64 billion USD. By 2020, [...]
  • Global Cybersecurity Market Driven by Increase in Cyber Attacks
    In recent years, the global market for cybersecurity has grown steadily, with the rapid adoption of cloud-based services. As more and more corporate and government organizations are realizing the importance of protecting data and intellectual property, the market for cybersecurity is going to expand. In 2014, the global market for cybersecurity was valued at 95.60 [...]
  • Global Epilepsy Drug Market Continues to Grow Steadily
    The global epilepsy drug market has grown steadily in recent years with increased sales of anti-epileptic drugs which are targeted at reducing seizures. Epilepsy is a condition which affects the brain and is characterized with repeated seizures in the patient. Treatment for epilepsy usually involves the use of medicines known as anti-epileptic drugs which prevents [...]
  • Global Meat and Poultry Product Market to Witness Steady Growth
    As global demand for meat and poultry products continues to rise, the market for meat and poultry is also expected to grow steadily. The market for meat and poultry products is driven by rise in disposable income, growing awareness among consumers about the importance of adding protein to their diet, and change in eating habits. [...]
  • Graft-Versus-Host Disease (GVHD) Treatment Market worth $407 million by 2018
  • The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm GlobalData. The company’s latest report* states …

  • Poland Pharmaceutical Industry Growing at 8.3% CAGR to 2020
  • Factors such as the growing elderly population, increasing availability of affordable medicines, and transparent regulatory guidelines will provide the necessary impetus for the growth of the Polish pharmaceutical market, but a decrease in mark-up prices and the country’s stringent drug …

  • Asia-Pacific, Led by China, Drive the Global Methanol Industry
  • China is driving the global methanol industry, with tremendous demand from both its energy and petrochemicals sectors. It accounts for 87.9% of Asia-Pacific’s (APAC) methanol capacity, and 51.9% of the global methanol capacity. Despite a large planned capacity increase in …

  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Graft-Versus-Host Disease Market Forecast to 2023
  • Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either …

  • Cameroon Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 58
    BMI View: Mobile health has strong growth potential in Cameroon, given the lack of health infrastructure and medical professionals. The use of mobile health will help to improve accessibility to healthcare, to some extent. However, we maintain that in order for Cameroon to reach its full potential, there needs to be much greater commitment to invest in healthcare services. Headline Expenditure Projections ? Pharmaceuticals: XAF148.82bn (USD300mn) in 2013 to XAF166.95bn (USD320mn) in 2014; +12.2%......
  • Tanzania Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 69
    BMI View: Sourcing accurate and reliable quantitative data on Tanzania's pharmaceutical market remains challenging due to substandard audits, porous sales channels, a high prevalence of counterfeits, questionable national statistics, dispensing without prescriptions, sizeable 'grey markets' and the widespread use of traditional remedies. BMI takes into account the import dependence of countries for medicines and assumes that economic growth as well as the resulting increase in the size of Tanzan......
  • Bulgaria Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 101
    BMI View: The Ministry of Health's plan to increase MAH fees, coupled with price cuts for generic drugs and freezes on OTC medicine prices indicate that the Bulgarian pharmaceutical market will not see meaningful growth in 2014. However, we expect a pickup in demand for innovative drugs to reinvigorate interest in the country, although it will continue to present a relatively small opportunity for drugmakers in the region. Headline Expenditure Projections ? Pharmaceuticals: BGN2.32bn (USD1.58bn)......
  • Taiwan Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 136
    BMI View: BMI believes that cost-containment policies will not place significant pressure on healthcare expenditure in Taiwan. This is because the majority of spending in the medical services sector goes towards salaries for doctors and nurses, which are difficult to cut back on without arousing political opposition. Meanwhile, the needs of the ageing population mean that demand is increasing for innovative pharmaceuticals and medical devices, which will sustain higher health expenditure. Taiwan......
  • Austria Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 65
    BMI View: Austria's economy is set to grow at a faster clip in the second half of 2014 and domestic consumer demand is poised to strengthen in this period. We have revised the healthcare and pharmaceutical market forecast slightly upwards to reflect this. The EUR-USD exchange rate continues to provide investment opportunities for overseas investors. In the medium term, Austria's pharmaceutical and healthcare spending will post weak growth as the government caps growth in public healthcare expend......
  • Sudan Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 56
    BMI View: Overall pharmaceutical sales in Sudan and South Sudan are to see double-digit growth, albeit from a low base. In addition, we highlight that high inflation, volatile currency exchange rates and civil unrests are some of the key risks that will continue to limit pharmaceutical growth potential in Sudan and South Sudan. Headline Expenditure Projections ? Pharmaceuticals: SDG2.60bn (USD560mn) in 2013 to SDG3.29bn (USD540mn) in 2014; +26.4% in local currency terms and -3.1% in US dollar te......
  • Slovenia Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 95
    ? BMI View: Political instability caused by the collapse of the coalition government and the resignation by the prime minister has increased the risk of a slowdown in GDP growth and a likely loss of momentum in structural reforms. Therefore, the burden of healthcare cuts, under pressure from the EU and IMF, will fall on the pharmaceutical industry. Although public healthcare funding had managed to eliminate its deficit in 2013, undertaking healthcare reform has proved to be politically difficult......
  • Singapore Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 131
    BMI View: The considerable increase in the government's healthcare expenditure highlights Singapore's commitment to provide better, more affordable healthcare services for its population, particularly the elderly. The government's aim to further increase its expenditure to 40% of the total health expenditure will bring about commercial benefits for healthcare players and pharmaceutical manufacturers, as it will potentially increase patient's access to healthcare. We highlight a need for the coun......
  • Romania Pharmaceuticals and Healthcare Report Q3 2014
    Published: 28-May-2014        Price: US $1295 Onwards        Pages: 114
    BMI View: Our above-consensus outlook for economic growth in Romania has borne out, with positive implications for the pharmaceutical sector. With wages set to rise and consumer spending continuing to grow at a rapid clip, consumer non-discretionary spending is set to tick higher. We see over-the-counter medicines and potentially generic medicines benefitting from an improving consumer picture. Over the longer term, Romania's competitive labour costs are set to catalyse an influx of manufacturin......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs